Pakistan Infection Control Market - Forecasts from 2020 to 2025
Pakistan infection control market is projected to reach US$29.883 million in 2025. In Pakistan, the top ten causes of death are Ischemic Heart Disease (8%), Cancer (8%), Lower-Respiratory Infections (8%), Stroke (6%), Diarrheal Diseases (6%), Neonatal Encephalopathy (5%), Chronic obstructive pulmonary disease (5%), TB (5%), Pre-Term Birth Complications (4%), and Diabetes (3%). Pakistan is one of three remaining countries where indigenous wild poliovirus (WPV) transmission has never been interrupted. The number of confirmed WPV cases increased to 198 in 2011. Also, in 2011, Pakistan began implementing a national action plan in response to the World Health Organisation (WHO) declaring a global polio emergency. Further, the Health care provision in Pakistan is the responsibility of the government. The health care system has expanded gradually with a large network of health facilities, workforce, and services across the country. Currently, the public health care system comprises 1,167 hospitals, 5,695 dispensaries, 5,464 basic health units, 675 rural health centers, 733 mother and child health centers and allied medical professionals i.e. doctors, nurses, midwives, and pharmacists. As of FY2016, there are 18,4711 doctors, 16,652 dentists, and the availability of 118,869 hospital beds in the country.
Cumulative health expenditures of federal and the provinces are estimated at Rs 384.57 billion for the fiscal year 2017-18 which is 31.75% higher than the actual expenditures of Rs 291.90 billion realized during the fiscal year 2016 – 17. A brief look into the previous year’s performance reveals that total health expenditures increased both in terms of growth and a percentage of GDP. It grew by 29.54% to stand at Rs 291.90 billion during the fiscal year 2016 – 17 against Rs 225.87 billion in 2015 – 16. Health expenditures surpassed the budget allocation of Rs 273.34 billion set for 2016-17. While in terms of GDP, health expenditure increased to 0.91 percent during the fiscal year 2016-17 from 0.77 recorded in 2015-16. During the months of Jul-February, 2017-18 health expenditures consumed 43.5 percent of budget allocation to reach Rs 167.16 billion against the expenditure of Rs 121.57 billion in the comparable period of the fiscal year 2016-17. In terms of growth, it increased by 37.51 percent. Viewed from GDP, it increased to 0.49 percent during July - February 2017-18 from 0.38 percent recorded in the same period of the fiscal year 2016-17.
Further, a total of Rs 15.0 billion was allocated in Prime Minister Health Programme (PSDP) 2017-18 for the two phases of the program. Further due to increased investments of healthcare by the year 2017, the number of public sector hospitals has increased to 1,211, 5,508 basic health units (BHUs), 676 rural health centers (RHCs) and 5,697 dispensaries. These facilities together with 208,007 doctors, 20,463 dentists, and 103,777 nurses bring the current ratio of one doctor for 957 persons, 9,730 people per dentist and availability of one hospital bed for 1,580 people and shows that number under each establishment is increasing. Therefore, with the prevalence of diseases, the involvement of the government and its subsequent expenditure on healthcare towards setting up of initiatives, among others to uphold the wellbeing of the patients as well as high patient turnover as exemplified by the incremental growth of total number beds till 2015 across various healthcare points, the need for adhering to strict infection prevention protocol by the healthcare segment of the nation is of paramount importance in order to prevent any further complications like hospital-acquired infection (HAI). This need will drive the demand for infection prevention products during the forecast thereby throttling the growth of the Infection Control Market of Pakistan during the forecast period.
Segmentation
Cumulative health expenditures of federal and the provinces are estimated at Rs 384.57 billion for the fiscal year 2017-18 which is 31.75% higher than the actual expenditures of Rs 291.90 billion realized during the fiscal year 2016 – 17. A brief look into the previous year’s performance reveals that total health expenditures increased both in terms of growth and a percentage of GDP. It grew by 29.54% to stand at Rs 291.90 billion during the fiscal year 2016 – 17 against Rs 225.87 billion in 2015 – 16. Health expenditures surpassed the budget allocation of Rs 273.34 billion set for 2016-17. While in terms of GDP, health expenditure increased to 0.91 percent during the fiscal year 2016-17 from 0.77 recorded in 2015-16. During the months of Jul-February, 2017-18 health expenditures consumed 43.5 percent of budget allocation to reach Rs 167.16 billion against the expenditure of Rs 121.57 billion in the comparable period of the fiscal year 2016-17. In terms of growth, it increased by 37.51 percent. Viewed from GDP, it increased to 0.49 percent during July - February 2017-18 from 0.38 percent recorded in the same period of the fiscal year 2016-17.
Further, a total of Rs 15.0 billion was allocated in Prime Minister Health Programme (PSDP) 2017-18 for the two phases of the program. Further due to increased investments of healthcare by the year 2017, the number of public sector hospitals has increased to 1,211, 5,508 basic health units (BHUs), 676 rural health centers (RHCs) and 5,697 dispensaries. These facilities together with 208,007 doctors, 20,463 dentists, and 103,777 nurses bring the current ratio of one doctor for 957 persons, 9,730 people per dentist and availability of one hospital bed for 1,580 people and shows that number under each establishment is increasing. Therefore, with the prevalence of diseases, the involvement of the government and its subsequent expenditure on healthcare towards setting up of initiatives, among others to uphold the wellbeing of the patients as well as high patient turnover as exemplified by the incremental growth of total number beds till 2015 across various healthcare points, the need for adhering to strict infection prevention protocol by the healthcare segment of the nation is of paramount importance in order to prevent any further complications like hospital-acquired infection (HAI). This need will drive the demand for infection prevention products during the forecast thereby throttling the growth of the Infection Control Market of Pakistan during the forecast period.
Segmentation
- By Product
- Disinfectants
- Sterilization
- Low-Temperature Sterilization
- Heat Sterilization
- Contract Sterilization
- By End User Industry
- Healthcare
- Food and Beverage
- Chemical
1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. PAKISTAN INFECTION CONTROL MARKET, BY PRODUCT
5.1. Introduction
5.2. Disinfectants
5.3. Sterilization
5.3.1. Low-Temperature Sterilization
5.3.2. Heat Sterilization
5.3.3. Contract Sterilization
6. PAKISTAN INFECTION CONTROL MARKET, BY END USER INDUSTRY
6.1. Introduction
6.2. Healthcare
6.3. Food and Beverage
6.4. Chemical
7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Vendor Competitiveness Matrix
8. COMPANY PROFILES
8.1. 3M
8.2. Belimed AG
8.3. Miele
8.4. Reckitt Benckiser
8.5. Tuttnauer
8.6. List is not Exhaustive*
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. PAKISTAN INFECTION CONTROL MARKET, BY PRODUCT
5.1. Introduction
5.2. Disinfectants
5.3. Sterilization
5.3.1. Low-Temperature Sterilization
5.3.2. Heat Sterilization
5.3.3. Contract Sterilization
6. PAKISTAN INFECTION CONTROL MARKET, BY END USER INDUSTRY
6.1. Introduction
6.2. Healthcare
6.3. Food and Beverage
6.4. Chemical
7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Vendor Competitiveness Matrix
8. COMPANY PROFILES
8.1. 3M
8.2. Belimed AG
8.3. Miele
8.4. Reckitt Benckiser
8.5. Tuttnauer
8.6. List is not Exhaustive*
